drugset / Trial / NCT04558502
Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
RandomizedParallel-groupOpen-labelTreatment
Summary
Although,bismuth-containing quadruple therapy has been highly recommended as first-line treatment regimen for H.pylori infection,it also has its problems and limitations in China.The primary resistance rates of metronidazole,clarithromycin and levofloxacin are all high in China.Besides that,tetracycline cannot be obtained and its complicated administration (four times daily) easily reduce patient compliance. In this study, we proposed to evaluate the eradication rate, safety, and compliance of a minocycline-based bismuth quadruple regimen.
Timeline
- Start
- 2022-01-05
- Primary completion
- 2022-06-05
- Completion
- 2022-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Minocycline | Small molecule | 100 mg | — |
| Background | Amoxicillin | Other / unclassified | 1000 mg | — |
| Background | Esomeprazole | Small molecule | 20 mg | — |
| Background | colloidal bismuth pectin | Unknown | 200 mg | — |
Indications
No indication recorded.